SCHEMBL25370300

SCHEMBL25370300

CS(=O)(=O)Nc1cccc(NC(=O)c2cc(C(=O)NCc3ccc(CN4CCOCC4)cc3)cs2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.51
▸ SMN1; SMN2 Q16637 5/20 0.49
▸ NPC1 O15118 4/20 0.49
▸ RAB9A P51151 4/20 0.49
▸ LMNA P02545 4/20 0.49
▸ TP53 P04637 3/20 0.49
▸ HIF1A Q16665 2/20 0.49
▸ EPAS1 Q99814 2/20 0.49
▸ TSHR P16473 1/20 0.48
▸ MEN1 O00255 3/20 0.47
▸ KMT2A Q03164 3/20 0.47
▸ KDM1A O60341 1/20 0.46
▸ RCOR1 Q9UKL0 1/20 0.46
▸ MAPT P10636 2/20 0.46
▸ MAPK1 P28482 1/20 0.46
▸ KDM4E B2RXH2 1/20 0.45
▸ POLB P06746 1/20 0.45
▸ EPHX2 P34913 1/20 0.45
▸ NR1H4 Q96RI1 1/20 0.45
▸ CA2 P00918 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30543961 1.00 ALDH1A1 (0.51) ALDH1A1SMN1; SMN2NPC1RAB9ALMNA
SCHEMBL25370105 0.92 NPC1 (0.56) ALDH1A1SMN1; SMN2NPC1RAB9ALMNA
SCHEMBL30543936 0.92 NPC1 (0.56) ALDH1A1SMN1; SMN2NPC1RAB9ALMNA
SCHEMBL30543894 0.91 EPHX2 (0.54) ALDH1A1SMN1; SMN2LMNAMEN1KMT2A
SCHEMBL25368567 0.91 EPHX2 (0.54) ALDH1A1SMN1; SMN2LMNAMEN1KMT2A
SCHEMBL25369081 0.82 DHX9 (0.48) RAB9A
SCHEMBL30543897 0.82 DHX9 (0.48) RAB9A
SCHEMBL25367369 0.79 KDR (0.55) MEN1KMT2AKDM4EPOLBEPHX2
SCHEMBL30543892 0.79 KDR (0.55) MEN1KMT2AKDM4EPOLBEPHX2
SCHEMBL25368505 0.77 DHX9 (0.47) ALDH1A1SMN1; SMN2MEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250179013-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. 2025-06-05 — — US claimed
WO-2023158795-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. (US) 2023-08-24 — — WO claimed
US-20250179013-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. 2025-06-05 — — US disclosed
WO-2023158795-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. (US) 2023-08-24 — — WO disclosed
WO-2023158795-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. (US) 2023-08-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250179013-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF DHX9, DHX29, DDX39B ALDH1A1 1127/4885SMN1; SMN2 645/4885NPC1 2484/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback